Tag: iVascular
“No signal of increased risk of long-term mortality” with paclitaxel-coated Luminor...
An ad hoc, two-year analysis of the EffPac study found no signal of increased risk of long-term mortality, nor any adverse events, within two...
MERLION trial six-month outcomes presented at VIVA late-breaking trial session
Six-month clinical outcomes of the MERLION trial were presented as part of the VIVA Late-Breaking Clinical Trials Livesteam (25 June), by Tjun Tang (Singapore...
Luminor DCB now reimbursed in France
It was recently announced that luminor 18 and luminor 35 DCBs (iVascular), are now listed on the French LPPR list for de novo lesions...
Experts discuss latest results from EFFPAC and TINTIN trials presented at...
NOTE: ONLY intended for healthcare professionals outside of the USA.
Ulf Teichgräber (Jena, Germany) and Koen Deloose (Dendermonde, Belgium) discuss the 24-month results of the...
TINTIN trial shows “impressive” results at six months
The six-month results of TINTIN (Treatment with the lumINor DCB and The IVolutioN self-expanding stent) trial have been revealed at the annual meeting of the Cardiovascular and...
Enrolment complete in T.I.N.T.I.N. study
iVascular has announced the completion of enrolment of patients in its T.I.N.T.I.N. (Treatment with the Luminor DCB and the iVolution self-expanding stent) study.
The effectiveness...
CX 2018: Ulf Teichgräber discusses EffPAC trial 12-month results
Ulf Teichgräber, Jena, Germany, discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018
iVascular initiates TINTIN Luminor trial
iVascular SLU has announced the initiation of the TINTIN trial, evaluating the combined therapy of Luminor drug-coated balloon (DCB) and iVolution self-expandable stent.
The TINTIN...
iVascular SLU receives Indian clearance for peripheral products
iVascular SLU has announced that it has received approval for selling its coronary and peripheral products in India.
The Indian medical devices market is the...
Luminor drug-coated balloon receives Canadian Medical Device Licence
iVascular has announced that its Luminor 14m peripheral balloon catheter with paclitaxel elution has received the Canadian Medical Device Licence (MDL).
Luminor 14m is a...
Luminor EffPAC study shows efficacy at six months
Data have been announced demonstrating the efficacy of iVascular’s Luminor drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) at six months. The...
Angiolite BTK below-the-knee sirolimus-eluting stent receives CE mark approval
iVascular has announced the release of Angiolite BTK, a sirolimus-eluting stent which has received CE mark approval for treating chronic and acute arterial lesions in...
Capturer 7F thrombus extraction catheter receives CE mark
iVascular has obtained CE mark for the thrombus extraction catheter Capturer 7F.
A company press release states that Capturer 7F has “outstanding extraction capacity” and “the...
LUMINOR Registry may help “reopen the door” for drug-coated balloons below...
The LUMINOR Registry is a real-world prospective multicentre study evaluating iVascular’s Luminor paclitaxel-eluting balloon for treating advanced limb ischaemia. Vascular News spoke to Vincent...
